OATP1B-type transport function is a determinant of aromatase inhibitor-associated arthralgia susceptibility.

IF 2 Q3 ONCOLOGY Cancer research communications Pub Date : 2025-03-10 DOI:10.1158/2767-9764.CRC-24-0475
Hanieh Taheri, Yang Li, Kevin M Huang, Eman Ahmed, Yan Jin, Thomas Drabison, Yan Yang, Samuel K Kulp, Nicholas A Young, Junan Li, Xiaolin Cheng, Kara N Corps, Christopher C Coss, Jennifer E Vaughn, Maryam B Lustberg, Alex Sparreboom, Shuiying Hu
{"title":"OATP1B-type transport function is a determinant of aromatase inhibitor-associated arthralgia susceptibility.","authors":"Hanieh Taheri, Yang Li, Kevin M Huang, Eman Ahmed, Yan Jin, Thomas Drabison, Yan Yang, Samuel K Kulp, Nicholas A Young, Junan Li, Xiaolin Cheng, Kara N Corps, Christopher C Coss, Jennifer E Vaughn, Maryam B Lustberg, Alex Sparreboom, Shuiying Hu","doi":"10.1158/2767-9764.CRC-24-0475","DOIUrl":null,"url":null,"abstract":"<p><p>Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is extensive, and this phenomenon may have important ramification for AI-associated arthralgia, a common toxicity of which the etiology remains unclear. We speculated that hepatic uptake transporters involved in the elimination of AIs play a crucial role in explaining this pharmacologic variability. Using an array of in silico, in vitro, in vivo, and human studies, we identified OATP1B1 and OATP1B3 (in humans) as well as the murine orthologue Oatp1b2 as transporters that regulate the initial step in the elimination of AIs. Genetic deficiency of this transport mechanism in mice was associated with elevated plasma levels of AIs and with concurrent increases in treatment-related arthralgia. In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is extensive, and this phenomenon may have important ramification for AI-associated arthralgia, a common toxicity of which the etiology remains unclear. We speculated that hepatic uptake transporters involved in the elimination of AIs play a crucial role in explaining this pharmacologic variability. Using an array of in silico, in vitro, in vivo, and human studies, we identified OATP1B1 and OATP1B3 (in humans) as well as the murine orthologue Oatp1b2 as transporters that regulate the initial step in the elimination of AIs. Genetic deficiency of this transport mechanism in mice was associated with elevated plasma levels of AIs and with concurrent increases in treatment-related arthralgia. In line with these findings, we found that low hepatic OATP1B-type transporter activity in patients with breast cancer was associated with an increase in AI-associated arthralgia. These findings shed light on the rate-limiting step in the elimination of AIs and suggest a rationale for the potential implementation of transporter biomarkers to predict susceptibility to AI-associated arthralgia and ultimately mitigate this debilitating toxicity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Age and sex differences in the prevalence of specific comorbidities among pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma patients at diagnosis. Branched-chain amino acid catabolism promotes ovarian cancer cell proliferation via phosphorylation of mTOR. LNS8801: An enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development. OATP1B-type transport function is a determinant of aromatase inhibitor-associated arthralgia susceptibility. IMGN853 induces autophagic cell death in combination therapy for ovarian cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1